<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791154</url>
  </required_header>
  <id_info>
    <org_study_id>20060534</org_study_id>
    <secondary_id>QUILT-2.013</secondary_id>
    <nct_id>NCT00791154</nct_id>
  </id_info>
  <brief_title>QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantCell, Inc.</source>
  <brief_summary>
    <textblock>
      This trial is titled &quot;A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based
      Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC).&quot;

      Part 1, the phase 1b portion of this study, is a multicenter, open-label investigation to
      identify safe dose levels of either AMG 102 or AMG 479 in combination with etoposide plus
      cisplatin or carboplatin in subjects with previously untreated extensive stage SCLC.

      Part 2, the phase 2 portion of this study, is a multicenter, double-blind, 3-arm
      investigation to evaluate overall survival of either AMG 102 or AMG 479 in combination with
      platinum-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 2: To estimate the relative treatment effect of platinum-based chemotherapy and AMG 479, and of platinum-based chemotherapy and AMG 102, compared to platinum-based chemotherapy and placebo as measured by the respective HR for overall survival</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs). Part 2: Overall survival (OS)</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities not defined as DLTs.</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-AMG 479 and anti-AMG 102 antibody formation</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax and Cmin for AMG 102 and AMG 479)</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR, DOR, TTP, PFS and OS rates at 10, 12, 24 and 36 months</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 and EORTC QLQ-LC13 scores</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded placebo and carboplatin or cisplatin and etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 479</intervention_name>
    <description>AMG 479 is administered to subjects</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide is administered to subjects</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered with Carboplatin and Etoposide</description>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102</intervention_name>
    <description>AMG 102 is administered to subjects</description>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is administered to some subjects in combination</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is administered to some subjects in combination</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Histologically or cytologically confirmed SCLC

          -  Extensive disease, defined by at least one of the following:

          -  No limited disease (ie, no disease confined to the ipsilateral hemithorax, which can
             be safely encompassed within a tolerable radiation field)

          -  Extrathoracic metastases

          -  Malignant pericardial or pleural effusion

          -  Contralateral hilar adenopathy

          -  Measurable or nonmeasurable disease, as defined by modified RECIST

          -  Eastern Cooperative Oncology Group (ECOG) status 0 or 1

          -  ≥18 years old

          -  Life expectancy (with therapy) ≥3 months

          -  Adequate hematologic, hepatic, coagulation, renal, and metabolic function

          -  Diabetes, if present, must be controlled, with glycosylated hemoglobin (HbA1C) ≤ 8%
             and fasting glucose levels ≤160 mg/dL

        Key Exclusion Criteria

          -  Prior chemotherapy, chemoradiation, or investigational agent for SCLC

          -  Prior radiotherapy to &gt;25% of the bone marrow

          -  Symptomatic or untreated central nervous system metastases (with exceptions)

          -  Currently or previously treated with biologic, immunologic or other therapies for SCLC

          -  Current serious or nonhealing wound or ulcer

          -  History of prior concurrent other malignancy (with exceptions)

          -  Thorombosis or vascular ischemic events within the last 12 months such as DVT, PE, TIA
             or MI

          -  Any clinically significant medical condition other than cancer (eg, cardiovascular
             disease or COPD), which could interfere with the safe delivery of study treatment or
             risk of toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <disposition_first_submitted>February 2, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 2, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 19, 2015</disposition_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extensive disease</keyword>
  <keyword>Extrathoracic metasasis</keyword>
  <keyword>Malignant pericardial effusion</keyword>
  <keyword>Malignant pleural effusion</keyword>
  <keyword>Contralateral hilar adenopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

